Navigation Links
ASAM Approves Prescription Drug Policy

CHEVY CHASE, Md., Jan. 26, 2012 /PRNewswire-USNewswire/ -- "Prescription drug diversion and the health consequences of prescription drug misuse and abuse should be of primary concern to all physicians," states American Society of Addiction Medicine (ASAM) Acting President, Stuart Gitlow, MD.  "Tens of thousands of Americans are overdosing on prescription pain medication and many of these prescriptions are coming from doctors' offices." 

Chronic pain and addiction are issues faced by patients from all walks of life and in all types of treatment settings.  And, yet, very few physicians are sufficiently educated about the potential psychiatric and addiction consequences of prescribing scheduled medications like opioid analgesics and sedative hypnotics (two of the most commonly misused classes of prescription medication).  The Centers for Disease Control and Prevention reports that the sale of prescription pain drugs has increased by 300% since 1999 and the most recent National Survey on Drug Use and Health (Substance Abuse and Mental Health Administration) reports that nearly 1 in 6 non-medical users of prescription pain killers got the drug through a prescription from a doctor.  Currently, there are no requirements that prescribers prove they are competent to prescribe these potentially lethal drugs. 

"Prescription drug use and overdose death are becoming a public health crisis," says Dr. Gitlow.  "Physicians and patients should understand the risks and benefits of using these powerful drugs and make educated treatment choices."  To that end, ASAM recommends that all health professionals who can prescribe scheduled medications must be included in any educational efforts to improve patient outcomes and public health.  One part of the solution is to mandate prescriber education for all health professionals licensed to prescribe, dispense or administer prescription drugs.  A public health response should also include patient education, training for medical students and residents in safe prescribing practices, pain medicine and addiction medicine, implementation of coordinated state prescription drug monitoring programs, and support for continued research on patterns of manufacture, distribution and sales of psychoactive drugs which have the potential for diversion and misuse. 

To read ASAM's Public Policy Statement on Measures to Counteract Prescription Drug Diversion, Misuse and Dependence, please click here.

The American Society for Addiction Medicine is a professional society representing close to 3,000 physicians dedicated to increasing access and improving quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addictions.

Contact: Alexis Geier-Horan
(301) 656-3920 x103

SOURCE American Society of Addiction Medicine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... 2016 The Biotechnology industry might ... present great opportunities to investors. assesses the recent ... (NYSE: XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):